After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory illnesses. Brand New Membership Level ...

"Today, we announce the beginning of an exciting new chapter for Novavax with the launch of a strategically important partnership with one of the world's leading vaccine companies," NVAX CEO John ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Novavax (NVAX) witnessed a jump in share price last session on above-average trading ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...